NCT04251585View on ClinicalTrials.gov

Intranasal Insulin in Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

February 4, 2020

Primary Completion Date

August 27, 2024

Study Completion Date

August 27, 2024

Conditions
Parkinson Disease
Interventions
DRUG

Regular Novolin R

Intranasal insulin

DRUG

Placebo

Intranasal placebo (0.9% saline)

Trial Locations (1)

55130

HealthPartners Neuroscience Center, Saint Paul

All Listed Sponsors
lead

HealthPartners Institute

OTHER

NCT04251585 - Intranasal Insulin in Parkinson's Disease | Biotech Hunter | Biotech Hunter